Bristol-Myers Squibb denies claims in Merck Sharp & Dohme’s misuse of market power case

Bristol-Myers Squibb 2021-08-06 3:06 pm By Miklos Bolza | Sydney

Please login to bookmark

Pharmaceutical giant Bristol-Myers Squibb will fight a case brought by Merck Sharp & Dohme alleging misuse of market power over stage IV melanoma treatments, telling the Federal Court on Friday it denied its rival’s claims.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au